3
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Refractory NTRK fusion–positive cancers
- Tumour stage
- Locally advanced or metastatic
- Control Arm
- Single arm trials
- Treatment Setting
- Treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion
Primary Outcome(s)
- Primary Outcome(s)
- ORR,DOR
- Evaluated Outcome
- ORR,DOR
- Form(s)
- Form 3
Outcome Data
- PFS Control
- 11.2 months
- ORR
- 57%
- DoR
- 10.4 months
Final Score (after adjustments)
- Preliminary non-curative score
- 3
- Final non-curative Score
- 3
- Issue date
- 23.07.2020
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; MFS, metastasis-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate; SD, stable disease; SSA, somatostatin analogue; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor, TTP, time to progression